Merit Medical Systems, Inc. issued a press release on January 13, 2025, disclosing its preliminary unaudited revenue for the year ending December 31, 2024, along with plans to unveil its fourth-quarter financial results and fiscal year 2025 guidance. The company reported a projected revenue range of approximately $1.355 billion to $1.357 billion for 2024, reflecting a year-over-year increase of approximately 7.7% to 7.9%.
According to the release, Merit’s preliminary constant currency revenue for 2024 rose in the range of around 8.4% to 8.6% compared to the previous year. The figures provided in the press release are based on the company’s current expectations and may be subject to adjustments following the finalization of customary financial review and audit processes.
Merit Medical Systems, Inc., traded on the NASDAQ under the ticker symbol MMSI, is a prominent global manufacturer and marketer of healthcare technology. The company, founded in 1987, is involved in developing, producing, and distributing proprietary medical devices used in various medical procedures across different fields.
It is crucial to note that the figures shared in the press release are preliminary and unaudited. Merit’s audited consolidated financial statements for the year ending December 31, 2024, are not yet finalized. As such, the preliminary revenue information disclosed should be considered management estimates as of the release date and are subject to potential variations from the audited results.
The company provided a cautionary statement regarding forward-looking statements, indicating that actual results might differ from anticipated results due to various risks and uncertainties outlined in Merit’s filings with the SEC. Investors should exercise caution and consider these factors when evaluating the information shared within the press release.
Merit Medical urges readers to review the complete reconciliation provided within the release for the non-GAAP financial measure of constant currency revenue and not to rely solely on this metric when assessing the company’s financial performance.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Merit Medical Systems’s 8K filing here.
Merit Medical Systems Company Profile
Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.
Further Reading
- Five stocks we like better than Merit Medical Systems
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 3 Warren Buffett Stocks to Buy Now
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Use the MarketBeat Excel Dividend Calculator
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
